Profil
Adam Watkinson worked as the Chief Scientific Officer at Acrux Ltd.
from 2005 to 2011.
He also worked as a Manager-Project & Delivery Research at Kyowa Kirin International Plc.
Dr. Watkinson received his undergraduate degree from the University of Bath and his MBA and doctorate from the University of Cardiff.
Anciens postes connus de Adam Watkinson
| Sociétés | Poste | Fin |
|---|---|---|
| ACRUX LIMITED | Directeur Technique/Scientifique/R&D | 20/05/2011 |
Kyowa Kirin International Plc
 Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Corporate Officer/Principal | - |
Formation de Adam Watkinson
| University of Cardiff | Doctorate Degree |
| University of Bath | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ACRUX LIMITED | Health Technology |
| Entreprise privées | 1 |
|---|---|
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Health Technology |